HAVCR2 and neoplasm: More importantly, higher expression of TIM-3 was associated with a poor prognosis in solid malignant [90] and accumulating preclinical models have verified the therapeutic benefit of TIM-3 blockade by regulating TME and restricting tumor growth especially in combination with PD-1 blockade [91].